European Leukemia Trial Registry
Trial: DACOTA

More Details
Title Phase III Trial of Decitabine with or without Hydroxyurea versus Hydroxyurea in CMML
Scientific Title A Randomized Phase III study of Decitabine with or without Hydroxyurea versus Hydroxyurea in patients with advanced proliferative Chronic Myelomonocytic Leukemia (GFM-DAC-CMML)
Short Title DACOTA
Trialgroup Deutsche MDS
Type of Trial multicentric, randomized, double-group
Disease Myelodysplastic Syndrome(MDS) Different risk groups
Age >= 18 years
Status Active
Start of Recruitment 31.10.2014
Leader Platzbecker, Prof. Dr. med., Uwe
Centre of Trial Universitätsklinikum Carl Gustav Carus, Dresden
Shortprotocol Shortprotocol
created 06.03.2015 Alexandra Lucaciu
changed 19.03.2015 Hanna Ebert
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org